Novel naphthyloxy derivatives - Potent histamine H3 receptor ligands. Synthesis and pharmacological evaluation

Bioorg Med Chem. 2018 May 15;26(9):2573-2585. doi: 10.1016/j.bmc.2018.04.023. Epub 2018 Apr 11.

Abstract

A series of 1- and 2-naphthyloxy derivatives were synthesized and evaluated for histamine H3 receptor affinity. Most compounds showed high affinities with Ki values below 100 nM. The most potent ligand, 1-(5-(naphthalen-1-yloxy)pentyl)azepane (11) displayed high affinity for the histamine H3 receptor with a Ki value of 21.9 nM. The antagonist behaviour of 11 was confirmed both in vitro in the cAMP assay (IC50 = 312 nM) and in vivo in the rat dipsogenia model (ED50 = 3.68 nM). Moreover, compound 11 showed positive effects on scopolamine induced-memory deficits in mice (at doses of 10 and 15 mg/kg) and an analgesic effect in the formalin test in mice with ED50 = 30.6 mg/kg (early phase) and ED50 = 20.8 mg/kg (late phase). Another interesting compound, 1-(5-(Naphthalen-1-yloxy)pentyl)piperidine (13; H3R Ki = 53.9 nM), was accepted for Anticonvulsant Screening Program at the National Institute of Neurological Disorders and Stroke/National Institute of Health (Rockville, USA). The screening was performed in the maximal electroshock seizure (MES), the subcutaneous pentylenetetrazole (scPTZ) and the 6-Hz psychomotor animal models of epilepsy. Neurologic deficit was evaluated by the rotarod test. Compound 13 inhibited convulsions induced by the MES with ED50 of 19.2 mg/kg (mice, i.p.), 17.8 (rats, i.p.), and 78.1 (rats, p.o.). Moreover, 13 displayed protection against the 6-Hz psychomotor seizures (32 mA) in mice (i.p.) with ED50 of 33.1 mg/kg and (44 mA) ED50 of 57.2 mg/kg. Furthermore, compounds 11 and 13 showed in vitro weak influence on viability of tested cell lines (normal HEK293, neuroblastoma IMR-32, hepatoma HEPG2), weak inhibition of CYP3A4 activity, and no mutagenicity. Thus, these compounds may be used as leads in a further search for histamine H3 receptor ligands with promising in vitro and in vivo activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics / administration & dosage
  • Analgesics / chemical synthesis
  • Analgesics / pharmacology
  • Analgesics / toxicity
  • Animals
  • Antazoline / pharmacology
  • Anticonvulsants / administration & dosage
  • Anticonvulsants / chemical synthesis
  • Anticonvulsants / pharmacology*
  • Anticonvulsants / toxicity
  • Atropine / pharmacology
  • Azepines / administration & dosage
  • Azepines / chemical synthesis
  • Azepines / pharmacology*
  • Azepines / toxicity
  • Dose-Response Relationship, Drug
  • Guinea Pigs
  • HEK293 Cells
  • Histamine H3 Antagonists / administration & dosage
  • Histamine H3 Antagonists / chemical synthesis
  • Histamine H3 Antagonists / pharmacology*
  • Histamine H3 Antagonists / toxicity
  • Humans
  • Ligands
  • Male
  • Mice
  • Naphthalenes / administration & dosage
  • Naphthalenes / chemical synthesis
  • Naphthalenes / pharmacology*
  • Naphthalenes / toxicity
  • Piperidines / administration & dosage
  • Piperidines / chemical synthesis
  • Piperidines / pharmacology*
  • Piperidines / toxicity
  • Rats, Wistar
  • Receptor, Muscarinic M3 / metabolism
  • Receptors, Histamine H1 / metabolism
  • Receptors, Histamine H3 / metabolism

Substances

  • Analgesics
  • Anticonvulsants
  • Azepines
  • Histamine H3 Antagonists
  • Ligands
  • Naphthalenes
  • Piperidines
  • Receptor, Muscarinic M3
  • Receptors, Histamine H1
  • Receptors, Histamine H3
  • Atropine
  • Antazoline